Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Respir Med ; 189: 106667, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34757277

RESUMEN

PURPOSE: Deep sedation is sometimes needed in acute respiratory distress syndrome. Ketamine is a sedative that has been shown to have analgesic and sedating properties without having a detrimental impact on hemodynamics. This pharmacological profile makes ketamine an attractive sedative, potentially reducing the necessity for other sedatives and vasopressors, but there are no studies evaluating its effect on these medications in patients requiring deep sedation for acute respiratory distress syndrome. MATERIALS AND METHODS: This is a retrospective, observational study in a single center, quaternary care hospital in southeast Texas. We looked at adults with COVID-19 requiring mechanical ventilation from March 2020 to September 2020. RESULTS: We found that patients had less propofol requirements at 72 h after ketamine initiation when compared to 24 h (median 34.2 vs 54.7 mg/kg, p = 0.003). Norepinephrine equivalents were also significantly lower at 48 h than 24 h after ketamine initiation (median 38 vs 62.8 mcg/kg, p = 0.028). There was an increase in hydromorphone infusion rates at all three time points after ketamine was introduced. CONCLUSIONS: In this cohort of patients with COVID-19 ARDS who required mechanical ventilation receiving ketamine we found propofol sparing effects and vasopressor requirements were reduced, while opioid infusions were not.


Asunto(s)
COVID-19/epidemiología , Sedación Profunda , Hipnóticos y Sedantes/administración & dosificación , Ketamina/administración & dosificación , Respiración Artificial , Síndrome de Dificultad Respiratoria/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Analgésicos Opioides/uso terapéutico , COVID-19/terapia , Utilización de Medicamentos/estadística & datos numéricos , Femenino , Humanos , Hidromorfona/uso terapéutico , Masculino , Persona de Mediana Edad , Norepinefrina/uso terapéutico , Propofol/uso terapéutico , Síndrome de Dificultad Respiratoria/terapia , Estudios Retrospectivos , Texas/epidemiología
2.
Cureus ; 12(7): e9139, 2020 Jul 11.
Artículo en Inglés | MEDLINE | ID: mdl-32789077

RESUMEN

Bilateral retrocerebellar arachnoid cysts are exceedingly rare. We report a case of a 38-year-old woman, who presented with progressive vertigo and was found to have bilateral retrocerebellar arachnoid cysts. The patient's clinical presentation was most consistent with benign positional peripheral vertigo, while the cysts were thought to be incidental findings. We review the literature on bilateral retrocerebellar arachnoid cysts and discuss their management.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...